BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/7/2024 9:19:40 AM | Browse: 493 | Download: 1214
Publication Name World Journal of Nephrology
Manuscript ID 98393
Country Russia
ISSN 2220-6124 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pediatrics
Manuscript Type Retrospective Study
Article Title Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study
Manuscript Source Invited Manuscript
All Author List Elvira Kalashnikova, Eugenia Isupova, Ekaterina Gaidar, Natalia Lubimova, Lyubov Sorokina, Irina Chikova, Maria Kaneva, Rinat Raupov, Olga Kalashnikova, Damir Aliev, Inna Gaydukova and Mikhail Kostik
Funding Agency and Grant Number
Funding Agency Grant Number
Ministry of Science and Higher Education of the Russian Federation 075-15-2022-301
Russian Science Foundation 22-45-08004
Corresponding Author Mikhail Kostik, MD, PhD, Professor, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Lytovskaya 2, Saint Petersburg 194100, Sankt-Peterburg, Russia. kost-mikhail@yandex.ru
Key Words Systemic lupus erythematosus; Rituximab; Rituximab BCD020 biosimilar; Anti-CD-20; Biologic; Children
Core Tip Systemic lupus erythematosus in children is a severe life-threatening disease, that requires systemic immune-suppressive therapy. Early biologic treatment in children with systemic lupus erythematosus can provide faster remission with a better corticosteroid-sparing effect.
Publish Date 2024-11-07 08:48
Citation

Kalashnikova E, Isupova E, Gaidar E, Lubimova N, Sorokina L, Chikova I, Kaneva M, Raupov R, Kalashnikova O, Aliev D, Gaydukova I, Kostik M. Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study. World J Nephrol 2024; 13(4): 98393

URL https://www.wjgnet.com/2220-6124/full/v13/i4/98393.htm
DOI https://dx.doi.org/10.5527/wjn.v13.i4.98393
Full Article (PDF) WJN-13-98393-with-cover.pdf